|
New York Press Releases
|
(EMAILWIRE.COM, May 20, 2012 ) New York, NY -- VFC's Stock House, an information and research outlet that brings ideas and opens discussions to a broad spectrum of investors, recaps last week's best stories and provides a look at multiple companies to watch during the coming trading week.
As expected, all eyes were on the historic Facebook IPO last week, although continued economic trouble in Europe probably deserved more attention and should prove to be a whole lot more relevant to the markets from here on out.
Although having only one full day of trading in the history books, Facebook is already starting to look like a dud to any investor not already on the inside leading into the IPO. Emotion and investing don't mix, and those that excitedly predicted swift increases in the FB share price when they flooded the Nasdaq market were thoroughly disappointed on Friday as the closing price was not even a percentage point higher than the open.
The most hyped IPO ever looks just like that right now - all hype and little substance, and with shares trading for a cap of 100 times earnings, it's going to take a whole lot more hype to keep the FB share price afloat.
One has to wonder just how much hype is left.
Last week it was argued that the IPO was geared more towards milking as many riches as possible for the insiders than it was for creating a stable trading market, and the headlines that poured from numerous media outlets over the weekend look to agree with that assessment. It could be a tough week ahead for Facebook, which at the end of the day is still a company out to prove to be more than just the latest fad.
An historic event it was, this Facebook IPO. Success, overnight millionaires and lavish spending sprees all resulted from a small idea that turned big.
NovaBay Pharmaceuticals (NBY): NovaBay could be a company whose share price might have become a whole lot more attractive during the recent downturn in the markets, having dropped from the $1.30 range to under a dollar at one point with no associated news announcement to justify such a fall. The move south was accompanied by higher-than-average volume, but not enough, in my opinion, to spark fears of a mass sell-off.
Ampio Pharmaceuticals (AMPE): Shares of Ampio Pharmaceuticals also dropped by nearly five percent on Friday, approaching the 52-week low after a run to nearly ten dollars last year sparked an intensive round of investor interest in the company.
Ampio has three pipeline products with significant potential chugging along through development, and a a few ORP diagnostic devices that measure oxidative stress in patients and are also worth noting as a potentially more accurate measure of a patient's total health than the current standard of care test of vital signs one receives upon entry to a doctor's office.
Synergy Pharmaceuticals (SGYP): Still hovering at right around the price of a recent stock offering, shares of Synergy Pharmaceuticals could prove to be quite the bargain, should the company's ongoing clinical trials turn out positive, as is generally expected, and should lead product candidate, Plecanatide, even remotely approach its billion-dollar potential upon approval in the indications of chronic idiopathic constipation (CIC) and constipation-predominant irritable bowel syndrome (IBS-C).
Cytosorbents (CTSO): The more impatient of investors looked to be unimpressed with the perceived slow progress of Cytosorbents to capitalize on the European approval of its CytoSorb blood purification technology on the open market in Germany, and the share price fell to below ten cents for a period last week as a result.
Celsius Holdings (CELH): Although down for the week, shares of Celsius Holdings closed up by ten percent on Friday on average volume. Another stable earnings report released this month provided a good indication that a solid foundation for growth is in place and CELH could be positioned to capitalize.
Full version available at: http://vfcsstockhouse.com/blog/article/-weekly-stock-watch-week-of-may-20-fb-nby-dndn-ampe-pfe-hgsi-sgyp-irwd-ctso-cvm-ttnp-kerx-celh-siri-mcd-agen-biel-bvti-abpi-amzn-nflx-imsc
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
About VFCsStockHouse.com:
VFC's Stock House is an information and research outlet that brings new ideas to the table and opens discussions for a broad spectrum of investors, with a strong focus on - but not limited to - biotech stocks and the pharmaceutical and healthcare sectors. VFC's Stock House provides individual company profiles, write-ups and reports as well as giving general insights into broader-market news through various 'Stock Watch' lists. At the conclusion of most weeks, VFC's Stock House issues a "Weekly Stock Watch" that examines news items, stocks and stories that made headlines during the previous trading week, but may also make headlines or influence trends during the upcoming week as well. The information contained within the pages of VFC’s Stock House are not intended to be taken as advice, but as a starting point where investors can follow up with their own DD and devise their own entry and exit strategies.
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com
|
|
|
|